{"id":"W2947606778","doi":"10.1200/jco.2019.37.15_suppl.9013","title":"KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Université de Sherbrooke","funders":"","keywords":"Pemetrexed; Medicine; Placebo; Oncology; Internal medicine; Pembrolizumab; Carboplatin; Docetaxel; Cisplatin; Chemotherapy; Cancer; Immunotherapy; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002779594,0.000776992,0.001289237,0.0004658048,0.0001625153,0.00098795,0.00114652,0.0008020943,0.007971114],"category_scores_gemma":[0.002656418,0.0003368576,0.003093309,0.000634282,0.0002553668,0.001114897,0.0007047118,0.001747782,0.0006279707],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009139777,"about_ca_system_score_gemma":0.000777426,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001249061,"about_ca_topic_score_gemma":0.003436987,"domain_scores_codex":[0.9991288,0.000434579,0.00006511816,0.0001675605,0.0001231696,0.0000808276],"domain_scores_gemma":[0.9989393,0.0002996136,0.0004589602,0.00008598896,0.00007177627,0.0001443552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.866819,0.001901858,0.01513406,0.00445239,0.01136932,0.00009138386,0.00009208848,0.002158354,0.005701076,0.0004795006,0.01165552,0.08014549],"study_design_scores_gemma":[0.6651156,0.1341656,0.134048,0.0006933379,0.03693809,0.0006821787,0.0001505227,0.00294036,0.003471229,0.0008558127,0.02081802,0.0001212519],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9087637,0.03278337,0.001735134,0.001852862,0.0009166325,0.002386926,0.04240567,0.0003159114,0.008839764],"genre_scores_gemma":[0.9691213,0.00433358,0.001740766,0.001134027,0.0004269806,0.001141648,0.01892338,0.00004739511,0.003130936],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007971114,"threshold_uncertainty_score":0.02666599,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07164292177969342,"score_gpt":0.4084465225844909,"score_spread":0.3368036008047975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}